• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.

作者信息

Piscolla E, Hakiki B, Pastò L, Razzolini L, Portaccio E, Amato M P

出版信息

J Neurol. 2013 Jun;260(6):1675-7. doi: 10.1007/s00415-013-6933-z. Epub 2013 May 5.

DOI:10.1007/s00415-013-6933-z
PMID:23645219
Abstract
摘要

相似文献

1
Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.芬戈莫德停药后一名儿童期起病的多发性硬化症患者出现的反弹现象。
J Neurol. 2013 Jun;260(6):1675-7. doi: 10.1007/s00415-013-6933-z. Epub 2013 May 5.
2
Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.因淋巴细胞减少停用芬戈莫德后多发性硬化症复发。
Neurol Sci. 2014 Sep;35(9):1485-6. doi: 10.1007/s10072-014-1800-y. Epub 2014 Apr 23.
3
Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?芬戈莫德治疗下的严重多发性硬化复发：偶然事件还是巧合？
Neurology. 2012 Mar 20;78(12):928-30. doi: 10.1212/WNL.0b013e31824c46ad. Epub 2012 Mar 7.
4
Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.芬戈莫德诱发一位年轻多发性硬化症女性出现房室传导缺陷——对可能的药物机制的见解
Eur J Clin Pharmacol. 2014 Mar;70(3):373-5. doi: 10.1007/s00228-013-1620-7. Epub 2013 Dec 6.
5
Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.芬戈莫德治疗下疱疹病毒再激活：一例严重单纯疱疹性脑炎病例
Neurology. 2015 Jun 9;84(23):2377-8. doi: 10.1212/WNL.0000000000001659. Epub 2015 May 8.
6
Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis.芬戈莫德诱发复发缓解型多发性硬化症患者哮喘病情恶化
Mult Scler. 2014 Nov;20(13):1792-3. doi: 10.1177/1352458514531844. Epub 2014 May 27.
7
Does fingolimod in multiple sclerosis patients cause macular edema?多发性硬化症患者使用芬戈莫德会导致黄斑水肿吗？
J Neurol. 2012 Feb;259(2):386-8. doi: 10.1007/s00415-011-6367-4. Epub 2012 Jan 10.
8
Rebound of disease activity during pregnancy after withdrawal of fingolimod.停用芬戈莫德后孕期疾病活动的反弹
Eur J Neurol. 2013 Aug;20(8):e109-10. doi: 10.1111/ene.12195.
9
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.芬戈莫德治疗复发缓解型多发性硬化症的安全性和疗效（FREEDOMS II）：一项双盲、随机、安慰剂对照、3 期临床试验。
Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28.
10
Effects of fingolimod in relapsing-remitting multiple sclerosis.芬戈莫德在复发缓解型多发性硬化症中的作用。
Lancet Neurol. 2014 Jun;13(6):526-7. doi: 10.1016/S1474-4422(14)70067-5. Epub 2014 Mar 28.

引用本文的文献

1
Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis.在一大群多发性硬化症患者的真实世界队列中，对停用芬戈莫德后疾病活动复发的频率、严重程度及独立危险因素进行评估。
Ther Adv Neurol Disord. 2023 Feb 6;16:17562864221150312. doi: 10.1177/17562864221150312. eCollection 2023.
2
Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS).芬戈莫德治疗复发缓解型多发性硬化症（RRMS）儿科患者的安全性、有效性及耐受性综述
Pediatric Health Med Ther. 2019 Nov 12;10:141-146. doi: 10.2147/PHMT.S220817. eCollection 2019.
3

本文引用的文献

1
Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.两名多发性硬化症患者停用芬戈莫德后疾病复发。
J Neurol. 2013 Jan;260(1):327-9. doi: 10.1007/s00415-012-6744-7. Epub 2012 Nov 16.
2
Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.用于复发缓解型多发性硬化症的芬戈莫德治疗撤药：6例报告。
Mult Scler. 2012 Nov;18(11):1636-9. doi: 10.1177/1352458512454773. Epub 2012 Jul 24.
3
Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations.芬戈莫德反弹：临床经验与管理考量综述
Neurol Ther. 2019 Dec;8(2):241-250. doi: 10.1007/s40120-019-00160-9. Epub 2019 Nov 1.
4
Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.停用芬戈莫德后多发性硬化症的严重恶化。
Clin Drug Investig. 2019 Sep;39(9):909-913. doi: 10.1007/s40261-019-00804-6.
5
Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.日本多发性硬化症患者停用芬戈莫德治疗后的疾病恶化
Intern Med. 2018 Sep 15;57(18):2647-2655. doi: 10.2169/internalmedicine.0793-18. Epub 2018 Apr 27.
6
A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo.停用芬戈莫德和安慰剂后多发性硬化症疾病活动的比较。
Mult Scler J Exp Transl Clin. 2017 Sep 27;3(3):2055217317730096. doi: 10.1177/2055217317730096. eCollection 2017 Jul-Sep.
7
Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.鞘氨醇-1-磷酸受体调节剂在复发缓解型和继发进展型多发性硬化中的获益-风险特征。
Drugs. 2017 Oct;77(16):1755-1768. doi: 10.1007/s40265-017-0814-1.
8
Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices.儿童多发性硬化症：诊断标准、影像学、组织病理学及治疗选择的最新进展
Curr Neurol Neurosci Rep. 2016 Jul;16(7):68. doi: 10.1007/s11910-016-0663-4.
9
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis.芬戈莫德治疗复发缓解型多发性硬化症的临床疗效、安全性及耐受性
Drug Healthc Patient Saf. 2015 Dec 11;7:157-67. doi: 10.2147/DHPS.S69640. eCollection 2015.
10
Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.因淋巴细胞减少停用芬戈莫德后多发性硬化症复发。
Neurol Sci. 2014 Sep;35(9):1485-6. doi: 10.1007/s10072-014-1800-y. Epub 2014 Apr 23.
停用芬戈莫德（FTY720）治疗后疾病活动的反弹。
Arch Neurol. 2012 Feb;69(2):262-4. doi: 10.1001/archneurol.2011.1057.
4
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.意大利多发性硬化症患者接受米托蒽醌治疗后出现急性髓系白血病。
Neurology. 2011 Nov 22;77(21):1887-95. doi: 10.1212/WNL.0b013e318238ee00. Epub 2011 Nov 9.
5
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.多发性硬化症患者中断那他珠单抗治疗期间疾病活动的复发。
Neurology. 2011 May 31;76(22):1858-65. doi: 10.1212/WNL.0b013e31821e7c8a. Epub 2011 May 4.
6
Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.环磷酰胺在多发性硬化症中的应用：科学原理、历史和新的治疗模式。
Ther Adv Neurol Disord. 2009 Nov;2(6):50-61. doi: 10.1177/1756285609344375.
7
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.那他珠单抗治疗的多发性硬化症患者停药后T2病变活动的反弹增加。
Neurology. 2008 Mar 25;70(13 Pt 2):1150-1. doi: 10.1212/01.wnl.0000265393.03231.e5. Epub 2007 Sep 13.